Screener
ClearPoint Neuro CLPT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash flows from financing activities | (1,845) | (1,362) |
| Net change in cash, cash equivalents and restricted cash | (10,457) | (7,717) |
| Cash, cash equivalents and restricted cash, beginning of period | 46,973 | 20,104 |
| Cash, cash equivalents and restricted cash, end of period | $36,516 | $12,387 |
| Cash and cash equivalents | 35,593 | 12,387 |
| Restricted cash included in other current assets and other assets, non-current | 923 | — |
| Total cash, cash equivalents and restricted cash | $36,516 | $12,387 |
| SUPPLEMENTAL CASH FLOW INFORMATION |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's cash & equivalents?
- ClearPoint Neuro (CLPT) reported cash & equivalents of $36.52M in Q1 2026.
- How has ClearPoint Neuro's cash & equivalents changed year-over-year?
- ClearPoint Neuro's cash & equivalents increased by 194.8% year-over-year, from $12.39M to $36.52M.
- What is the long-term trend for ClearPoint Neuro's cash & equivalents?
- Over 5 years (2020 to 2025), ClearPoint Neuro's cash & equivalents has grown at a 18.5% compound annual growth rate (CAGR), from $20.1M to $46.97M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about ClearPoint Neuro's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude